Jack Y.  Zhang net worth and biography

Jack Zhang Biography and Net Worth

Dr. Jack Zhang, Ph.D., co-founded Amphastar Pharmaceuticals in 1996 and has served as Chief Executive Officer, President, Chief Scientific Officer, and Board of Directors of Amphastar for over 20 years. With 40 years of leading industry expertise in Pharmaceutical and Biotechnology companies both domestically and internationally, Dr. Zhang has been the facilitator and builder of world-class technology management and product development teams. Dr. Zhang has a successful track record in leading the Amphastar team, receiving numerous FDA approvals of important and Block Buster medications in both start-ups and scaled growth stages.

As the Company's Chief Scientific Officer, Dr. Zhang oversees the scientific research and technology operations. Dr. Zhang also advises new process development and process scale-ups. Further, he provides scientific and regulatory guidance when the Company makes strategic decisions.

Dr. Zhang received a Ph.D. in Chemistry from the State University of New York at Stony Brook and was a Post-Doctoral Research Associate at the California Institute of Technology.

What is Jack Y. Zhang's net worth?

The estimated net worth of Jack Y. Zhang is at least $98.94 million as of May 18th, 2022. Dr. Zhang owns 2,156,523 shares of Amphastar Pharmaceuticals stock worth more than $98,941,275 as of December 3rd. This net worth evaluation does not reflect any other assets that Dr. Zhang may own. Learn More about Jack Y. Zhang's net worth.

How do I contact Jack Y. Zhang?

The corporate mailing address for Dr. Zhang and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on Jack Y. Zhang's contact information.

Has Jack Y. Zhang been buying or selling shares of Amphastar Pharmaceuticals?

Jack Y. Zhang has not been actively trading shares of Amphastar Pharmaceuticals during the past quarter. Most recently, Jack Y. Zhang sold 67,046 shares of the business's stock in a transaction on Wednesday, May 18th. The shares were sold at an average price of $34.14, for a transaction totalling $2,288,950.44. Following the completion of the sale, the chief executive officer now directly owns 2,156,523 shares of the company's stock, valued at $73,623,695.22. Learn More on Jack Y. Zhang's trading history.

Who are Amphastar Pharmaceuticals' active insiders?

Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amphastar Pharmaceuticals?

In the last year, insiders at the sold shares 20 times. They sold a total of 349,556 shares worth more than $19,025,420.83. The most recent insider tranaction occured on November, 12th when EVP Rong Zhou sold 6,893 shares worth more than $336,929.84. Insiders at Amphastar Pharmaceuticals own 27.1% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.

Information on this page was last updated on 11/12/2024.

Jack Y. Zhang Insider Trading History at Amphastar Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2022Sell67,046$34.14$2,288,950.442,156,523View SEC Filing Icon  
2/18/2021Sell30,467$18.59$566,381.53
2/11/2021Sell19,823$19.06$377,826.382,246,988View SEC Filing Icon  
2/9/2021Sell40,886$18.92$773,563.122,246,988View SEC Filing Icon  
2/4/2021Sell25,570$18.89$483,017.302,246,988View SEC Filing Icon  
2/2/2021Sell37,931$18.43$699,068.332,246,988View SEC Filing Icon  
9/11/2019Sell300,000$20.82$6,246,000.002,147,316View SEC Filing Icon  
12/13/2018Sell29,689$20.99$623,172.112,115,894View SEC Filing Icon  
12/11/2018Sell66,757$21.47$1,433,272.792,115,894View SEC Filing Icon  
5/15/2018Buy25,000$16.08$402,000.002,065,619View SEC Filing Icon  
9/20/2016Sell444,199$21.03$9,341,504.971,295,685View SEC Filing Icon  
12/11/2015Sell63,300$14.25$902,025.00920,117View SEC Filing Icon  
12/8/2015Sell68,117$14.71$1,002,001.07920,117View SEC Filing Icon  
12/3/2015Sell38,583$15.45$596,107.35920,117View SEC Filing Icon  
6/15/2015Sell45,382$16.29$739,272.78View SEC Filing Icon  
6/12/2015Sell160,495$16.23$2,604,833.85View SEC Filing Icon  
6/9/2015Sell193,758$16.43$3,183,443.94View SEC Filing Icon  
See Full Table

Jack Y. Zhang Buying and Selling Activity at Amphastar Pharmaceuticals

This chart shows Jack Y Zhang's buying and selling at Amphastar Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More

Today's Range

Now: $44.80
Low: $44.80
High: $46.11

50 Day Range

MA: $47.78
Low: $43.62
High: $53.40

2 Week Range

Now: $44.80
Low: $36.56
High: $65.92

Volume

69,075 shs

Average Volume

397,423 shs

Market Capitalization

$2.15 billion

P/E Ratio

14.93

Dividend Yield

N/A

Beta

0.78